JOURNEY MEDICAL CORPOR

Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults

11 7 2023 08:30:20 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023

03 7 2023 08:00:00 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects

13 6 2023 08:30:59 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

22 5 2023 16:01:31 提供 Nasdaq GlobeNewswire

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023

19 5 2023 16:01:27 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Announces Postponement of First Quarter Financial Results Release and Conference Call

11 5 2023 16:01:01 提供 Nasdaq GlobeNewswire

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023

04 5 2023 09:00:26 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

29 3 2023 16:01:11 提供 Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023

22 3 2023 09:00:54 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial

16 3 2023 08:30:32 提供 Nasdaq GlobeNewswire

Journey Medical Corporation to Participate in the 35th Annual ROTH Conference

07 3 2023 08:30:31 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial Officer

20 1 2023 16:01:30 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

10 1 2023 08:30:15 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29

20 12 2022 08:30:55 提供 Nasdaq GlobeNewswire

Journey Medical Corporation to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference

05 12 2022 16:05:00 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

10 11 2022 16:01:01 提供 Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022

03 11 2022 08:52:17 提供 Nasdaq GlobeNewswire

Journey Medical Corporation to Participate in Upcoming October 2022 Investor Conferences

04 10 2022 08:30:00 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

30 8 2022 08:30:00 提供 Nasdaq GlobeNewswire

Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

09 8 2022 16:01:00 提供 Nasdaq GlobeNewswire